The Aquaculture Vaccines market is projected to reach US$ 706.2 Bn by 2030. And registering a CAGR of around 13.4% over the forecast period 2021 – 2030.
Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/38535
Growth Factors
The growing demand for aquatic animal-derived food products, such as oil, caviar, protein powders, and meat, is encouraging farmers to use vaccinations for to gain higher profitability. Due to the rising urbanization, consumers are becoming more aware of the nutritious value of animal protein. The demand for healthy, sustainable, aquaculture vaccines and high-quality meat products that have fewer or no drugs is also increasing rapidly. Thus, the need for healthy breeding of aquatic animals is increasing, which is expected to fuel the demand for aquaculture vaccines, thereby boosting the market growth.
Report Coverage
| Report Scope | Details |
| Market Size | USD 7.06.2 Mn by 2030 |
| Growth Rate | CAGR of 13.4% From 2021 to 2030 |
| Base Year | 2020 |
| Historic Data | 2017 to 2020 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Product, Route of administration, Application |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Mentioned | Zoetis; Phibro Animal Health Corporation; Elanco; Merck & Co., Inc.; KBNP; CAVAC; Kyoto Biken Laboratories, Inc.; Nisseiken Co., Ltd.; Vaxxinova International BV; HIPRA |
Report Highlights
Inactivated vaccines held the largest share of 44.89% in 2020. Inactivated bacterial and viral vaccines are manufactured by the fermentation of the disease-causing pathogens in large quantities. Inactivating agents such as formalin are then introduced to kill all the microorganisms. These inactivated organisms elicit an immune response as they retain their basic shape, original antigen characteristics, and structure.
The recombinant vaccines segment is expected to register a CAGR of 10.65% from 2021 to 2030. Recombinant vaccines help evoke a strong immune response in the vaccinated fish, as they can mimic naturally occurring infections. It is also easier to produce recombinant vaccines in large quantities and on a commercial scale.
The injected segment held the largest share of 46.73% in 2020. Apex-IHN by Elanco is the first DNA vaccine licensed in Canada for protection against IHNV in healthy salmonid fishes. The oral segment is expected to expand at the highest CAGR of 10.7% during the forecast period. Oral vaccination has several advantages over other routes of administration.
The bacterial segment held the largest share of 53.94% in 2020. As per Aquatic Animal Health Research by the USDA, bacterial species of more than 20 genera have been identified as causative agents behind Aquatic diseases. They affect over 20 species of freshwater and marine water fishes.
The viral segment is expected to expand at the fastest CAGR of 10.74% during the forecast period. As per a report by the Responsible Use of Medicines in Agriculture Alliance (RUMA), the key groups of fish farmed via aquaculture, which are routinely vaccinated, are Atlantic salmon, rainbow trout, and Atlantic cod.
Europe held the largest revenue share of over 35.0%. The key factors driving this regional market include Norway being the largest salmon exporter, supportive initiatives by the government and private sector, rising human concerns over the incidence of antimicrobial resistance, and the presence of key players.
Key Players
- Zoetis
- Phibro Animal Health Corporation
- Elanco
- Merck & Co., Inc.
- KBNP
- CAVAC
- Kyoto Biken Laboratories, Inc.
- Nisseiken Co., Ltd.
- Vaxxinova International BV
- HIPRA
Market Segmentation
- Product
- Attenuated Live Vaccines
- Inactivated Vaccines
- Subunit Vaccines
- DNA Vaccines
- Recombinant Vaccines
- Route Of Administration
- Oral
- Injected
- Immersion & Spray
- Application
- Bacterial
- Viral
- Parasitic
- Regional
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Italy
- Spain
- Norway
- Denmark
- Ireland
- Eastern Europe
- Croatia
- Czech Republic
- Hungary
- Poland
- Russia
- Romania
- Bulgaria
- Asia Pacific
- Japan
- South Korea
- Taiwan
- Indonesia
- Malaysia
- Singapore
- Thailand
- Philippines
- Vietnam
- Latin America
- Brazil
- Mexico
- Argentina
- Chile
- Colombia
- Peru
- Ecuador
- Middle East & Africa
- South Africa
- Saudi Arabia
- Israel
- Egypt
- North America
Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38535
Reasons to Purchase this Report:
– Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
– Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
– Market value USD Million and volume Units Million data for each segment and sub-segment
– Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
– Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
Table of Contents
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Aquaculture Vaccines Market, By Product
7.1. Aquaculture Vaccines Market, by Product, 2021-2030
7.1.1. Attenuated Live Vaccines
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. Inactivated Vaccines
7.1.2.1. Market Revenue and Forecast (2017-2030)
7.1.3. Subunit Vaccines
7.1.3.1. Market Revenue and Forecast (2017-2030)
7.1.4. DNA Vaccines
7.1.4.1. Market Revenue and Forecast (2017-2030)
7.1.5. Recombinant Vaccines
7.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global Aquaculture Vaccines Market, By Route Of Administration
8.1. Aquaculture Vaccines Market, by Route Of Administration, 2021-2030
8.1.1. Oral
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Injected
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Immersion & Spray
8.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Aquaculture Vaccines Market, By Application
9.1. Aquaculture Vaccines Market, by Application, 2021-2030
9.1.1. Bacterial
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Viral
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Parasitic
9.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Aquaculture Vaccines Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Product (2017-2030)
10.1.2. Market Revenue and Forecast, by Route Of Administration (2017-2030)
10.1.3. Market Revenue and Forecast, by Application (2017-2030)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.1.4.2. Market Revenue and Forecast, by Route Of Administration (2017-2030)
10.1.4.3. Market Revenue and Forecast, by Application (2017-2030)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.1.5.2. Market Revenue and Forecast, by Route Of Administration (2017-2030)
10.1.5.3. Market Revenue and Forecast, by Application (2017-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.2. Market Revenue and Forecast, by Route Of Administration (2017-2030)
10.2.3. Market Revenue and Forecast, by Application (2017-2030)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.4.2. Market Revenue and Forecast, by Route Of Administration (2017-2030)
10.2.4.3. Market Revenue and Forecast, by Application (2017-2030)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.5.2. Market Revenue and Forecast, by Route Of Administration (2017-2030)
10.2.5.3. Market Revenue and Forecast, by Application (2017-2030)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.6.2. Market Revenue and Forecast, by Route Of Administration (2017-2030)
10.2.6.3. Market Revenue and Forecast, by Application (2017-2030)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.7.2. Market Revenue and Forecast, by Route Of Administration (2017-2030)
10.2.7.3. Market Revenue and Forecast, by Application (2017-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.2. Market Revenue and Forecast, by Route Of Administration (2017-2030)
10.3.3. Market Revenue and Forecast, by Application (2017-2030)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.4.2. Market Revenue and Forecast, by Route Of Administration (2017-2030)
10.3.4.3. Market Revenue and Forecast, by Application (2017-2030)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.5.2. Market Revenue and Forecast, by Route Of Administration (2017-2030)
10.3.5.3. Market Revenue and Forecast, by Application (2017-2030)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.6.2. Market Revenue and Forecast, by Route Of Administration (2017-2030)
10.3.6.3. Market Revenue and Forecast, by Application (2017-2030)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.7.2. Market Revenue and Forecast, by Route Of Administration (2017-2030)
10.3.7.3. Market Revenue and Forecast, by Application (2017-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.2. Market Revenue and Forecast, by Route Of Administration (2017-2030)
10.4.3. Market Revenue and Forecast, by Application (2017-2030)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.4.2. Market Revenue and Forecast, by Route Of Administration (2017-2030)
10.4.4.3. Market Revenue and Forecast, by Application (2017-2030)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.5.2. Market Revenue and Forecast, by Route Of Administration (2017-2030)
10.4.5.3. Market Revenue and Forecast, by Application (2017-2030)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.6.2. Market Revenue and Forecast, by Route Of Administration (2017-2030)
10.4.6.3. Market Revenue and Forecast, by Application (2017-2030)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.7.2. Market Revenue and Forecast, by Route Of Administration (2017-2030)
10.4.7.3. Market Revenue and Forecast, by Application (2017-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.5.2. Market Revenue and Forecast, by Route Of Administration (2017-2030)
10.5.3. Market Revenue and Forecast, by Application (2017-2030)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.5.4.2. Market Revenue and Forecast, by Route Of Administration (2017-2030)
10.5.4.3. Market Revenue and Forecast, by Application (2017-2030)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.5.5.2. Market Revenue and Forecast, by Route Of Administration (2017-2030)
10.5.5.3. Market Revenue and Forecast, by Application (2017-2030)
Chapter 11. Company Profiles
11.1. Zoetis
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Phibro Animal Health Corporation
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Elanco
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Merck & Co., Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. KBNP
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. CAVAC
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Company 7
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Kyoto Biken Laboratories, Inc.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Nisseiken Co., Ltd.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Vaxxinova International BV
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
11.11. HIPRA
11.11.1. Company Overview
11.11.2. Product Offerings
11.11.3. Financial Performance
11.11.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38535
Contact Us:
Vision Research Reports
Call: +1 9197 992 333
